Quality of life in breast cancer patients during chemotherapy and concurrent therapy with a mistletoe extract

Phytomedicine

Volumn 18, Issue 2-3, 2011, Pages 151-157

  Eisenbraun, J ^a   Scheer, R ^a   Kroz M ^b   Schad, F ^b   Huber, R ^c  

^a ABNOBA GMBH   (Germany)

^b Hospital Havelhöhe   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

AbnobaVISCUM ; Breast cancer; Complementary; Health Related Quality of Life; Mistletoe; QLQ C30; Tolerability

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; VISCUM ALBUM EXTRACT; VISCUM ALBUM LECTIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; DERMATITIS; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INJECTION SITE REACTION; LASSITUDE; MAJOR CLINICAL STUDY; MALAISE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QLQ BR23 QUESTIONNAIRE; QLQ C30 QUESTIONNAIRE; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; RECOMMENDED DRUG DOSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LONGITUDINAL STUDIES; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; VISCUM ALBUM; YOUNG ADULT;

EID: 78651322711     PISSN: 09447113     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.phymed.2010.06.013     Document Type: Article

References (28)

1. N.K. Aaronson, S. Ahmedzai, B. Bergman, M. Bullinger, A. Cull, N.J. Duez, A. Filiberti, H. Flechtner, S.B. Fleishman, and J.C. De Haes The European Organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology J. Natl. Cancer Inst. 85 1993 365 376
2. Abnoba GmbH Directions for Use of AbnobaVISCUM with Summary of Product Characteristics, Pforzheim 2003 Abnoba GmbH Germany
3. V. Arndt, H. Merx, C. Stegmaier, H. Ziegler, and H. Brenner Persistence of restrictions in quality of life from the first to the third year after diagnosis in women with breast cancer J. Clin. Oncol. 23 2005 4945 4953
4. J. Bohlius, K. Schmidlin, C. Brillant, G. Schwarzer, S. Trelle, J. Seidenfeld, M. Zwahlen, M. Clarke, O. Weingart, S. Kluge, M. Piper, D. Rades, D.P. Steensma, B. Djulbegovic, M.F. Fey, I. Ray-Coquard, M. Machtay, V. Moebus, G. Thomas, M. Untch, M. Schumacher, M. Egger, and A. Engert Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials Lancet 373 2009 1532 1542
5. A. Bottomley, and P. Therasse Quality of life in patients undergoing systemic therapy for advanced breast cancer Lancet Oncol. 3 2002 620 628
6. J.E. Bower Behavioral symptoms in patients with breast cancer and survivors J. Clin. Oncol. 26 2008 768 777
7. A. Büssing, C. Stumpf, W. Tröger, and M. Schietzel Course of mitogen-stimulated T lymphocytes in cancer patients treated with Viscum album extracts Anticancer Res. 27 2007 2903 2910
8. J.K. Carroll, S. Kohli, K.M. Mustian, J.A. Roscoe, and G.R. Morrow Pharmacologic treatment of cancer-related fatigue Oncologist 12 Suppl. 1 2007 43 51
9. K.A. Donovan, P.B. Jacobsen, M.A. Andrykowski, E.M. Winters, L. Balducci, U. Malik, D. Kenady, and P. Mcgrath Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer J. Pain Symptom Manage. 28 2004 373 380
10. German Federal Institute for Drugs and Medical Devices, 1998. Notification from November 11th, 1998. Recommendations for planning, conductance and analysis of observational studies. Bundesanzeiger No. 229 from 04.12.1998.
11. C. Gutenbrunner, M. Girke, F. Dimeo, H. Matthes, and M. Kröz Das Cancer Fatigue Syndrom - Eine Übersicht. The cancer fatigue syndrome - an overview Phys. Med. Rehab. Kuror. 20 2010 86 91
12. B.-M. Heiny, V. Albrecht, and J. Beuth Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract Anticancer Res. 18 1998 583 586
13. M.A. Horneber, G. Bueschel, R. Huber, K. Linde, M. Rostock The Cochrane Collaboration Mistletoe therapy in oncology, Review Cochrane Database Syst. Rev. The Cochrane Lib. 2008 1 69
14. R. Huber, R. Klein, P.A. Berg, R. Lüdtke, and M. Werner Effects of a lectin- and a viscotoxin-rich mistletoe preparation on clinical and hematologic parameters: a placebo-controlled evaluation in healthy subjects J. Altern. Complement. Med. 8 2002 857 866
15. R. Huber, M. Rostock, R. Goedl, R. Lüdtke, K. Urech, S. Buck, and R. Klein Mistletoe treatment induces GM-CSF- and IL-5 production by PBMC and increases blood granulocyte- and eosinophil counts: a placebo controlled randomized study in healthy subjects Eur. J. Med. Res. 10 2005 411 418
16. D.A. Karnofsky, W.H. Abelmann, C.F. Lloyd, and J.H. Burchenal The use of nitrogen mustards in the palliative treatment of carcinoma with particular reference to bronchogenic carcinoma Cancer 1 1948 634 656
17. M. Kröz, F. Schad, B. Matthes, H. Pickartz, and M. Girke Blut- und Gewebseosinophilie, Mistellektin-Antikörper und Lebensqualität bei einer Mammakarzinom-Patientin unter intratumoraler und subkutaner Misteltherapie Forsch. Komplementärmed. Klass. Naturheilkd. 9 2002 160 167
18. Lange-Lindberg, A.M., Velasco-Garrido, M., Busse, R., 2006, Misteltherapie als begleitende Behandlung zur Reduktion der Toxizität der Chemotherapie maligner Erkrankungen. Mistletoe treatment for minimising side effects for anticancer chemotherapy. Health Technology Assessment Report, Köln, http://www.dimdi.de, 1-97.
19. M. Martin, A. Lluch, M.A. Segui, A. Ruiz, M. Ramos, E. Adrover, A. Rodriguez-Lescure, R. Grosse, L. Calvo, C. Fernandez-Chacon, M. Roset, A. Anton, D. Isla, P.M. Del Prado, L. Iglesias, J. Zaluski, A. Arcusa, J.M. Lopez-Vega, M. Munoz, and J.R. Mel Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen Ann. Oncol. 17 2006 1205 1212
20. S.A. McLachlan, G.M. Devins, and P.J. Goodwin Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ-C30) as a measure of psychosocial function in breast cancer patients Eur. J. Cancer 34 1998 510 517
21. G.C. Nagel, S. Schmidt, B.M. Strauss, and D. Katenkamp Quality of life in breast cancer patients: a cluster analytic approach. Empirically derived subgroups of the EORTC-QLQ BR 23 - a clinically oriented assessment Breast Cancer Res. Treat. 68 2001 75 87
22. B.K. Piao, Y.X. Wang, G.R. Xie, U. Mansmann, H. Matthes, J. Beuth, and H.S. Lin Impact of complementary mistletoe extract treatment on quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial Anticancer Res. 24 2004 303 309
23. M. Schink, W. Tröger, A. Dabidian, A. Goyert, H. Scheuerecker, J. Meyer, I.U. Fischer, and F. Glaser Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. A randomized phase III trial Forsch. Komplementarmed. Klass. Naturheilkd. 14 2007 9 17
24. V.F. Semiglasov, V.V. Stepula, A. Dudov, W. Lehmacher, and U. Mengs The standardised mistletoe extract PS76A2 improves QoL in patients with breast cancer receiving adjuvant CMF chemotherapy: a randomised, placebo-controlled, double-blind, multicentre clinical trial Anticancer Res. 24 2004 1293 1302
25. V.F. Semiglazov, V.V. Stepula, A. Dudov, J. Schnitker, and U. Mengs Quality of life is improved in breast cancer patients by Standardised Mistletoe Extract PS76A2 during chemotherapy and follow-up: a randomised, placebo-controlled, double-blind, multicentre clinical trial Anticancer Res. 26 2006 1519 1529
26. K. Shimozuma Quality of life assessment Breast Cancer 9 2002 100 106
27. M.A. Sprangers, A. Cull, K. Bjordal, M. Groenvold, N.K. Aaronson EORTC Study Group on Quality of Life The European Organization for Research and Treatment of Cancer. Approach to quality of life assessment: guidelines for developing questionnaire modules Qual. Life Res. 2 1993 287 295
28. J.M. Watters, J.C. Yau, K. O'Rourke, E. Tomiak, and S.Z. Gertler Functional status is well maintained in older women during adjuvant chemotherapy for breast cancer Ann. Oncol. 14 2003 1744 1750